BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21277283)

  • 21. HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44.
    Luescher IF; Romero P; Kuznetsov D; Rimoldi D; Coulie P; Cerottini JC; Jongeneel CV
    J Biol Chem; 1996 May; 271(21):12463-71. PubMed ID: 8647853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription.
    Laduron S; Deplus R; Zhou S; Kholmanskikh O; Godelaine D; De Smet C; Hayward SD; Fuks F; Boon T; De Plaen E
    Nucleic Acids Res; 2004; 32(14):4340-50. PubMed ID: 15316101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4.
    Marcar L; Ihrig B; Hourihan J; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Hupp TR; Meek DW
    PLoS One; 2015; 10(5):e0127713. PubMed ID: 26001071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The KRAB-associated co-repressor KAP-1 is a coiled-coil binding partner, substrate and activator of the c-Fes protein tyrosine kinase.
    Delfino FJ; Shaffer JM; Smithgall TE
    Biochem J; 2006 Oct; 399(1):141-50. PubMed ID: 16792528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The melanoma antigen genes--any clues to their functions in normal tissues?
    Ohman Forslund K; Nordqvist K
    Exp Cell Res; 2001 May; 265(2):185-94. PubMed ID: 11302683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
    Jin J; Liu BZ; Wu ZM
    J Cancer Res Ther; 2015 Nov; 11 Suppl():C271-4. PubMed ID: 26612451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis.
    Peikert T; Specks U; Farver C; Erzurum SC; Comhair SA
    Cancer Res; 2006 May; 66(9):4693-700. PubMed ID: 16651421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6).
    Cho HJ; Caballero OL; Gnjatic S; Andrade VC; Colleoni GW; Vettore AL; Outtz HH; Fortunato S; Altorki N; Ferrera CA; Chua R; Jungbluth AA; Chen YT; Old LJ; Simpson AJ
    Cancer Immun; 2006 Dec; 6():12. PubMed ID: 17137291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structures of Two Melanoma-Associated Antigens Suggest Allosteric Regulation of Effector Binding.
    Newman JA; Cooper CD; Roos AK; Aitkenhead H; Oppermann UC; Cho HJ; Osman R; Gileadi O
    PLoS One; 2016; 11(2):e0148762. PubMed ID: 26910052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HP1 proteins: a potential role for Krüppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing.
    Ryan RF; Schultz DC; Ayyanathan K; Singh PB; Friedman JR; Fredericks WJ; Rauscher FJ
    Mol Cell Biol; 1999 Jun; 19(6):4366-78. PubMed ID: 10330177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin.
    Marcar L; Maclaine NJ; Hupp TR; Meek DW
    Cancer Res; 2010 Dec; 70(24):10362-70. PubMed ID: 21056992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation.
    Kasuga C; Nakahara Y; Ueda S; Hawkins C; Taylor MD; Smith CA; Rutka JT
    J Neurosurg Pediatr; 2008 Apr; 1(4):305-13. PubMed ID: 18377306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.
    Wischnewski F; Friese O; Pantel K; Schwarzenbach H
    Mol Cancer Res; 2007 Jul; 5(7):749-59. PubMed ID: 17634428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells.
    Sakurai T; Itoh K; Higashitsuji H; Nagao T; Nonoguchi K; Chiba T; Fujita J
    J Biol Chem; 2004 Apr; 279(15):15505-14. PubMed ID: 14739298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of KAP-1-associated complexes negatively regulating the Ey and β-major globin genes in the β-globin locus.
    Yang D; Ma Z; Lin W; Yang J; Tian C; Wei H; Jiang Y; He F
    J Proteomics; 2013 Mar; 80():132-44. PubMed ID: 23291531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer.
    Hartmann S; Zwick L; Scheurer MJJ; Fuchs AR; Brands RC; Seher A; Böhm H; Kübler AC; Müller-Richter UDA
    Clin Oral Investig; 2018 Apr; 22(3):1477-1486. PubMed ID: 29034444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel small compounds that restore E-cadherin expression and inhibit tumor cell motility and invasiveness.
    Hirano T; Satow R; Kato A; Tamura M; Murayama Y; Saya H; Kojima H; Nagano T; Okabe T; Fukami K
    Biochem Pharmacol; 2013 Nov; 86(10):1419-29. PubMed ID: 24035834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes.
    Miyashiro I; Kuo C; Huynh K; Iida A; Morton D; Bilchik A; Giuliano A; Hoon DS
    Clin Chem; 2001 Mar; 47(3):505-12. PubMed ID: 11238304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.
    Celegato M; Messa L; Goracci L; Mercorelli B; Bertagnin C; Spyrakis F; Suarez I; Cousido-Siah A; Travé G; Banks L; Cruciani G; Palù G; Loregian A
    Cancer Lett; 2020 Feb; 470():115-125. PubMed ID: 31693922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.